Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Identifieur interne : 001E99 ( PubMed/Corpus ); précédent : 001E98; suivant : 001F00Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Auteurs : Joaquim Bellmunt ; Thian Kheoh ; Margaret K. Yu ; Matthew R. Smith ; Eric J. Small ; Peter F A. Mulders ; Karim Fizazi ; Dana E. Rathkopf ; Fred Saad ; Howard I. Scher ; Mary-Ellen Taplin ; Ian D. Davis ; Dirk Schrijvers ; Andrew Protheroe ; Arturo Molina ; Peter De Porre ; Thomas W. Griffin ; Johann S. De Bono ; Charles J. Ryan ; Stéphane OudardSource :
- European urology [ 1873-7560 ] ; 2016.
Abstract
The duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
DOI: 10.1016/j.eururo.2015.10.021
PubMed: 26508309
Links to Exploration step
pubmed:26508309Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.</title>
<author><name sortKey="Bellmunt, Joaquim" sort="Bellmunt, Joaquim" uniqKey="Bellmunt J" first="Joaquim" last="Bellmunt">Joaquim Bellmunt</name>
<affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Joaquim_Bellmunt@dfci.harvard.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name>
<affiliation><nlm:affiliation>Janssen Research & Development, San Diego, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yu, Margaret K" sort="Yu, Margaret K" uniqKey="Yu M" first="Margaret K" last="Yu">Margaret K. Yu</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name>
<affiliation><nlm:affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name>
<affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name>
<affiliation><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name>
<affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name>
<affiliation><nlm:affiliation>University of Montréal, Montréal, Québec, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name>
<affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Taplin, Mary Ellen" sort="Taplin, Mary Ellen" uniqKey="Taplin M" first="Mary-Ellen" last="Taplin">Mary-Ellen Taplin</name>
<affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Davis, Ian D" sort="Davis, Ian D" uniqKey="Davis I" first="Ian D" last="Davis">Ian D. Davis</name>
<affiliation><nlm:affiliation>Monash University and Eastern Health, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schrijvers, Dirk" sort="Schrijvers, Dirk" uniqKey="Schrijvers D" first="Dirk" last="Schrijvers">Dirk Schrijvers</name>
<affiliation><nlm:affiliation>ZNA Middelheim Oncology Clinic, Medical Oncology, Antwerp, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Protheroe, Andrew" sort="Protheroe, Andrew" uniqKey="Protheroe A" first="Andrew" last="Protheroe">Andrew Protheroe</name>
<affiliation><nlm:affiliation>Churchill Hospital, Oxford, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W" last="Griffin">Thomas W. Griffin</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name>
<affiliation><nlm:affiliation>The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name>
<affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Oudard, Stephane" sort="Oudard, Stephane" uniqKey="Oudard S" first="Stéphane" last="Oudard">Stéphane Oudard</name>
<affiliation><nlm:affiliation>Georges Pompidou Hospital, University René Descartes, Paris, France.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26508309</idno>
<idno type="pmid">26508309</idno>
<idno type="doi">10.1016/j.eururo.2015.10.021</idno>
<idno type="wicri:Area/PubMed/Corpus">001E99</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E99</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.</title>
<author><name sortKey="Bellmunt, Joaquim" sort="Bellmunt, Joaquim" uniqKey="Bellmunt J" first="Joaquim" last="Bellmunt">Joaquim Bellmunt</name>
<affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Joaquim_Bellmunt@dfci.harvard.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name>
<affiliation><nlm:affiliation>Janssen Research & Development, San Diego, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yu, Margaret K" sort="Yu, Margaret K" uniqKey="Yu M" first="Margaret K" last="Yu">Margaret K. Yu</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name>
<affiliation><nlm:affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name>
<affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name>
<affiliation><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name>
<affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name>
<affiliation><nlm:affiliation>University of Montréal, Montréal, Québec, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name>
<affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Taplin, Mary Ellen" sort="Taplin, Mary Ellen" uniqKey="Taplin M" first="Mary-Ellen" last="Taplin">Mary-Ellen Taplin</name>
<affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Davis, Ian D" sort="Davis, Ian D" uniqKey="Davis I" first="Ian D" last="Davis">Ian D. Davis</name>
<affiliation><nlm:affiliation>Monash University and Eastern Health, Victoria, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schrijvers, Dirk" sort="Schrijvers, Dirk" uniqKey="Schrijvers D" first="Dirk" last="Schrijvers">Dirk Schrijvers</name>
<affiliation><nlm:affiliation>ZNA Middelheim Oncology Clinic, Medical Oncology, Antwerp, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Protheroe, Andrew" sort="Protheroe, Andrew" uniqKey="Protheroe A" first="Andrew" last="Protheroe">Andrew Protheroe</name>
<affiliation><nlm:affiliation>Churchill Hospital, Oxford, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W" last="Griffin">Thomas W. Griffin</name>
<affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name>
<affiliation><nlm:affiliation>The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name>
<affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Oudard, Stephane" sort="Oudard, Stephane" uniqKey="Oudard S" first="Stéphane" last="Oudard">Stéphane Oudard</name>
<affiliation><nlm:affiliation>Georges Pompidou Hospital, University René Descartes, Paris, France.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">European urology</title>
<idno type="eISSN">1873-7560</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">26508309</PMID>
<DateCreated><Year>2016</Year>
<Month>06</Month>
<Day>15</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>06</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>69</Volume>
<Issue>5</Issue>
<PubDate><Year>2016</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>European urology</Title>
<ISOAbbreviation>Eur. Urol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.</ArticleTitle>
<Pagination><MedlinePgn>924-32</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2015.10.021</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0302-2838(15)01002-7</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if prior endocrine therapy duration is an indicator of abiraterone acetate (AA) sensitivity.</AbstractText>
<AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Post-hoc exploratory analysis of randomised phase 3 studies examining post-docetaxel (COU-AA-301) or chemotherapy-naïve mCRPC (COU-AA-302) patients receiving AA. The treatment effect on overall survival (OS), radiographic progression-free survival (rPFS), and prostate-specific antigen (PSA) response analysed by quartile duration of prior gonadotropin-releasing hormone agonists (GnRHa) or androgen receptor (AR) antagonist.</AbstractText>
<AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were randomised to AA (1000mg, orally once daily) plus prednisone (5mg, orally twice daily) or placebo plus prednisone. Prior endocrine therapy was GnRHa (COU-AA-301, n=1127 [94%]; COU-AA-302, n=1057 [97%], 45.1 mo or 36.7 mo median duration, respectively) and/or orchiectomy (COU-AA-301, n=78 [7%] COU-AA-302, n=44 [4%]); castrated patients received prior AR antagonists (COU-AA-301, n=1015 [85%]; COU-AA-302, n=1078 [99%], 15.7 mo or 16.1 mo median duration, respectively).</AbstractText>
<AbstractText Label="OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS" NlmCategory="METHODS">Cox model was used to obtain hazard ratio and associated 95% confidence interval with statistical inference by log rank statistic.</AbstractText>
<AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">Clinical benefit with AA was observed for OS, rPFS, and PSA response for nearly all quartiles with GnRHa or AR antagonists in both COU-AA-301 and COU-AA-302. In COU-AA-301, patients with a longer duration of prior endocrine therapy tended to have greater AA OS, rPFS, and PSA response benefit, with lead-time chemotherapy bias potentially impacting COU-AA-301 results. Time to castration resistance was not captured. This analysis is limited as a post-hoc exploratory analysis.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the COU-AA-301 and COU-AA-302 studies, AA produced clinical benefits regardless of prior endocrine therapy duration in patients with mCRPC.</AbstractText>
<AbstractText Label="PATIENT SUMMARY" NlmCategory="RESULTS">Metastatic castration-resistant prostate cancer patients derived clinical benefits with abiraterone acetate regardless of prior endocrine therapy duration.</AbstractText>
<CopyrightInformation>Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellmunt</LastName>
<ForeName>Joaquim</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Joaquim_Bellmunt@dfci.harvard.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kheoh</LastName>
<ForeName>Thian</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, San Diego, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Margaret K</ForeName>
<Initials>MK</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Los Angeles, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>Matthew R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Small</LastName>
<ForeName>Eric J</ForeName>
<Initials>EJ</Initials>
<AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mulders</LastName>
<ForeName>Peter F A</ForeName>
<Initials>PF</Initials>
<AffiliationInfo><Affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fizazi</LastName>
<ForeName>Karim</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rathkopf</LastName>
<ForeName>Dana E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Saad</LastName>
<ForeName>Fred</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>University of Montréal, Montréal, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Scher</LastName>
<ForeName>Howard I</ForeName>
<Initials>HI</Initials>
<AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taplin</LastName>
<ForeName>Mary-Ellen</ForeName>
<Initials>ME</Initials>
<AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Davis</LastName>
<ForeName>Ian D</ForeName>
<Initials>ID</Initials>
<AffiliationInfo><Affiliation>Monash University and Eastern Health, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schrijvers</LastName>
<ForeName>Dirk</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>ZNA Middelheim Oncology Clinic, Medical Oncology, Antwerp, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Protheroe</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Churchill Hospital, Oxford, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molina</LastName>
<ForeName>Arturo</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Menlo Park, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Porre</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Beerse, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Griffin</LastName>
<ForeName>Thomas W</ForeName>
<Initials>TW</Initials>
<AffiliationInfo><Affiliation>Janssen Research & Development, Los Angeles, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Bono</LastName>
<ForeName>Johann S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo><Affiliation>The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ryan</LastName>
<ForeName>Charles J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Oudard</LastName>
<ForeName>Stéphane</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Georges Pompidou Hospital, University René Descartes, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>10</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Eur Urol</MedlineTA>
<NlmUniqueID>7512719</NlmUniqueID>
<ISSNLinking>0302-2838</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2004 Jun 14;90(12):2317-25</RefSource>
<PMID Version="1">15150570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2013 Aug;190(2):429-38</RefSource>
<PMID Version="1">23665272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Sep 27;367(13):1187-97</RefSource>
<PMID Version="1">22894553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2015 Feb;193(2):491-9</RefSource>
<PMID Version="1">25444753</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Sep 1;107(5):975-81</RefSource>
<PMID Version="1">16862573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2013 May;39(3):275-89</RefSource>
<PMID Version="1">23107383</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Oct 2;376(9747):1147-54</RefSource>
<PMID Version="1">20888992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Apr;24(4):1017-25</RefSource>
<PMID Version="1">23152362</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Oct;13(10):983-92</RefSource>
<PMID Version="1">22995653</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Jul;24(7):1807-12</RefSource>
<PMID Version="1">23576708</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2014 Nov;66(5):815-25</RefSource>
<PMID Version="1">24647231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2015 Jan;67(1):30-2</RefSource>
<PMID Version="1">25108578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Genitourin Cancer. 2011 Dec;9(2):95-103</RefSource>
<PMID Version="1">21958520</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2015 Jan;67(1):23-9</RefSource>
<PMID Version="1">25018038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2014 Feb;65(2):467-79</RefSource>
<PMID Version="1">24321502</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jul 31;371(5):424-33</RefSource>
<PMID Version="1">24881730</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 May 26;364(21):1995-2005</RefSource>
<PMID Version="1">21612468</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2015 Sep;51(14):1946-52</RefSource>
<PMID Version="1">26208462</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73</RefSource>
<PMID Version="1">7918112</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jan 10;368(2):138-48</RefSource>
<PMID Version="1">23228172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Feb;16(2):152-60</RefSource>
<PMID Version="1">25601341</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2006 Jan;175(1):27-34</RefSource>
<PMID Version="1">16406864</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2013 Nov;49(17):3648-57</RefSource>
<PMID Version="1">23973186</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jul 18;369(3):213-23</RefSource>
<PMID Version="1">23863050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jul 29;363(5):411-22</RefSource>
<PMID Version="1">20818862</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abiraterone acetate</Keyword>
<Keyword MajorTopicYN="N">Androgen receptor antagonists</Keyword>
<Keyword MajorTopicYN="N">Gonadotropin-releasing hormone</Keyword>
<Keyword MajorTopicYN="N">Prednisone</Keyword>
<Keyword MajorTopicYN="N">Prostate cancer</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>05</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>10</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>10</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>10</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>10</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26508309</ArticleId>
<ArticleId IdType="pii">S0302-2838(15)01002-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.eururo.2015.10.021</ArticleId>
<ArticleId IdType="pmc">PMC5465643</ArticleId>
<ArticleId IdType="mid">NIHMS866511</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:26508309 |texte= Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26508309" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |